Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-08-01 00:00:00 ET · period of report 2025-07-30 · accession 0001415889-25-020866 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-08-01 | 2025-07-30 | KNSA | Popovits Kimberly J | Dir | M - OptEx | $20.87 | 0 | 77.1K | New | $0 |
| DM | 2025-08-01 | 2025-07-30 | KNSA | Popovits Kimberly J | Dir | M - OptEx | $0.00 | -64.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-07-30 | M | A | 45,748 | $10.36 | 58,294 | D | — | — | |
| 2 | Common | Class A Ordinary Share | 2025-07-30 | M | D | 64,508 | $29.90 | 12,546 | D | — | — | (F1) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.66 and $30.07. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 3 | Common | Class A Ordinary Share | 2025-07-30 | M | A | 18,760 | $15.47 | 77,054 | D | — | — | |
| 4 | Derivative | Share Option | 2025-07-30 | M | D | 45,748 | $0.00 | 0 | D | $10.36 · — to 2028-02-29 | 45,748 Class A Ordinary Shares | (F2) The option is fully vested and exercisable. |
| 5 | Derivative | Share Option | 2025-07-30 | M | D | 18,760 | $0.00 | 0 | D | $15.47 · — to 2029-05-28 | 18,760 Class A Ordinary Shares | (F2) The option is fully vested and exercisable. |